Phase I/II Ex Vivo Gene Therapy Clinical Trial for Recessive Dystrophic Epidermolysis Bullosa Using Skin Equivalent Grafts Genetically Corrected with a COL7A1-Encoding SIN Retroviral Vector (GENEGRAFT)

Volume 25, Issue 2

https://doi.org/10.1089/humc.2014.2508

Abstract

Get full access to this article

View all access options for this article.

References

1.

ClinicalTrials.gov. Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB). ClinicalTrials.gov Identifier: NCT01874769.